Methylprednisone
- Generic Name
- Methylprednisone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O5
- CAS Number
- 91523-05-6
- Unique Ingredient Identifier
- 621XR2W6OP
- Background
Methylprednisone has been used in trials studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and Acute Lymphocytic Leukemia, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 50
- Registration Number
- NCT04791345
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 2
- Registration Number
- NCT04269850
- Locations
- 🇷🇺
Pavlov First Saint-Petersburg State Medical University, Saint Petersburg, Russian Federation
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02921789
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT01780844
- Locations
- 🇺🇸
Site US10038, Pittsburgh, Pennsylvania, United States
🇺🇸Site US10007, Atlanta, Georgia, United States
🇺🇸Site US10018, Chicago, Illinois, United States
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00968253
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00282308
- Locations
- 🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States
🇺🇸Borgess Research Institute, Kalamazoo, Michigan, United States
🇺🇸Justus Fiechtner MD - PP, Lansing, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.